Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Trustpilot revenue jumps 23% on U.S. and Enterprise momentum (Investing.com) +++ TRUSTPILOT Aktie -19,64%

ARMATA Aktie

 >ARMATA Aktienkurs 
4.66 EUR    -4.5%    (TradegateBSX)
Ask: 4.76 EUR / 626 Stück
Bid: 4.66 EUR / 642 Stück
Tagesumsatz: 260 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
ARMATA Aktie über LYNX handeln
>ARMATA Performance
1 Woche: -10,3%
1 Monat: +6,7%
3 Monate: -31,6%
6 Monate: -51,3%
1 Jahr: +83,6%
laufendes Jahr: -18,2%
>ARMATA Aktie
Name:  ARMATA PHARMACEUT.
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US04216R1023 / A2PKLC
Symbol/ Ticker:  TG1N (Frankfurt)
Kürzel:  FRA:TG1N, ETR:TG1N, TG1N:GR
Index:  -
Webseite:  https://www.armatapharma...
Profil:  Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections. The company’s current work centers on ph..
>Volltext..
Marktkapitalisierung:  172.47 Mio. EUR
Unternehmenswert:  422.5 Mio. EUR
Umsatz:  4.78 Mio. EUR
EBITDA:  -28.84 Mio. EUR
Nettogewinn:  -165.69 Mio. EUR
Gewinn je Aktie:  -4.57 EUR
Schulden:  270.68 Mio. EUR
Liquide Mittel:  20.65 Mio. EUR
Operativer Cashflow:  -21.92 Mio. EUR
Bargeldquote:  0.1
Umsatzwachstum:  -19.29%
Gewinnwachstum:  -647.57%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  ARMATA
Letzte Datenerhebung:  15.09.26
>ARMATA Kennzahlen
Aktien/ Unternehmen:
Aktien: 37.18 Mio. St.
Frei handelbar: 31.14%
Leerverk. Aktien: -
Rückkaufquote: -2.12%
Mitarbeiter: 61
Umsatz/Mitarb.: 0.07 Mio. EUR
Analysten:
Analystenrating: Strong buy
Kursziel: 225.28%
Bewertung:
KGV: -
KGV lG: -
KUV: 58.54
KBV: -
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: 66.88%
Gewinnmarge: -3467.04%
Operative Marge: -636.55%
Managementeffizenz:
Gesamtkaprendite: -225.11%
Eigenkaprendite: -
>ARMATA Peer Group
Gesundheit, Infektionskrankheiten/ Impfstoffentwicklung/ Antibiotika
 
14.09.26 - 14:18
 Armata Pharmaceuticals Aktie steigt nach FDA-Status als "Breakthrough Therapy" (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
14.09.26 - 13:03
 Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02 (PR Newswire)
 
Designation is driven by compelling Phase 2 clinical data in patients with complicated Staphylococcus aureus bacteremia showing AP-SA02 may offer substantial improvement over available therapies Potentially accelerating the path to market for this innovative antibacterial treatment......
10.09.26 - 13:03
 Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference (PR Newswire)
 
LOS ANGELES, Sept. 10, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of......
12.08.26 - 22:24
 Armata Pharmaceuticals GAAP EPS of -$0.27 beats by $0.18, revenue of $2.51M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
12.08.26 - 22:06
 Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update (PR Newswire)
 
LOS ANGELES, Aug. 12, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of......
21.07.26 - 14:30
 Armata Pharmaceuticals (ARMP) Stock Jumps 12.2%: Will It Continue to Soar? (Zacks)
 
Armata Pharmaceuticals (ARMP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road....
20.07.26 - 13:15
 Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02 (PR Newswire)
 
FDA submissions address all feedback on clinical, CMC, and regulatory topics from the End-of-Phase 2 meeting Four AP-SA02 engineering runs completed; clinical trial material production is the next planned manufacturing step Phase 3 superiority study remains on track to initiate in the......
13.07.26 - 13:01
 Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia (PR Newswire)
 
Fulfills important regulatory milestone for AP-SA02 on the path toward a future BLA and supports expansion into pediatric patients LOS ANGELES, July 13, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology......
23.06.26 - 16:30
 Armata gains $2.5M extra funding from DoD for lead program (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
23.06.26 - 15:01
 Armata Pharmaceuticals Aktie steigt nach zusätzlicher Finanzierung durch US-Verteidigungsministerium (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
23.06.26 - 13:02
 Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02 (PR Newswire)
 
Supports Phase 3 readiness of AP-SA02 Non-dilutive DoD funding totals $28.7M to date LOS ANGELES, June 23, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of......
13.05.26 - 22:57
 Armata Pharmaceuticals GAAP EPS of -$3.16 misses by $2.78, revenue of $0.79M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
13.05.26 - 22:36
 Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update (PR Newswire)
 
Entered into secured credit agreement with Innoviva for $25 million maturing in 2029 LOS ANGELES, May 13, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of......
07.05.26 - 13:06
 Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02 (PR Newswire)
 
Enables more frequent FDA engagement, rolling Biologic License Application review, and the potential for Accelerated Approval and Priority Review upon successful clinical development Advances AP-SA02 on a faster path to potential approval and patient access LOS ANGELES, May 7, 2026......
04.05.26 - 13:03
 Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology" (PR Newswire)
 
Describes structure of phage P7-1, included in Armata's Pseudomonas aeruginosa phage cocktail, AP-PA02 LOS ANGELES, May 4, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the......
27.04.26 - 13:03
 Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. to its Board of Directors (PR Newswire)
 
LOS ANGELES, April 27, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of......
26.03.26 - 09:12
 Armata Pharmaceuticals GAAP EPS of -$3.42, revenue of $1.1M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
25.03.26 - 21:06
 Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results (PR Newswire)
 
LOS ANGELES, March 25, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of......
19.03.26 - 12:03
 Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update (PR Newswire)
 
LOS ANGELES, March 19, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of......
23.02.26 - 14:54
 Armata Pharmaceuticals: Aktie legt nach FDA-Sonderstatus zu (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Hora ruit - Die Stunde stürzt dahin. - Nomen Nescio
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!